Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Second Quarter & Six-Months Ended ...
April 27 2015 - 8:30AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that it plans to report its fiscal second quarter and
six-months ended March 31, 2015 financial results before the U.S.
markets open on May 7, 2015. Enanta management will host a
conference call at 8:30 a.m. ET to discuss these results and
Enanta’s research and development pipeline.
Conference Call and Webcast InformationTo participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 11:30
a.m. Eastern time on May 7, 2015, through 11:59 p.m. Eastern time
on May 12, 2015 by dialing (855) 859-2056 from the U.S. or (404)
537-3406 for international callers. The passcode for both the live
call and the replay is 28434645. A live audio webcast of the call
and replay can be accessed by visiting the “Calendar of Events”
section on the “Investors” page of Enanta’s website at
www.enanta.com.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta is discovering, and in some cases developing, novel
inhibitors designed for use against the hepatitis C virus (HCV).
These inhibitors include members of the direct acting antiviral
(DAA) inhibitor classes – protease (partnered with AbbVie), NS5A,
and nucleotide polymerase – as well as a host-targeted antiviral
(HTA) inhibitor class targeted against cyclophilin. Enanta’s lead
protease inhibitor, paritaprevir, is part of AbbVie’s recently
approved HCV treatment regimens. In addition, Enanta has a
preclinical program in non-alcoholic steatohepatitis, or NASH,
which is a condition that results in liver inflammation and damage
caused by a buildup of fat in the liver.
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024
